Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database
To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II–III serous borderline ovarian tumors (BOTs). A multi-institutional retrospective study was conducted within the MITO Group. A total of 91 patients were recruited. The median follow-up t...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2021-06, Vol.161 (3), p.825-831 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 831 |
|---|---|
| container_issue | 3 |
| container_start_page | 825 |
| container_title | Gynecologic oncology |
| container_volume | 161 |
| creator | Falcone, Francesca Breda, Enrico Ferrandina, Gabriella Malzoni, Mario Perrone, Anna M. Cormio, Gennaro Di Donato, Violante Frigerio, Luigi Mangili, Giorgia Raspagliesi, Francesco Festi, Anna Scibilia, Giuseppe Biglia, Nicoletta Sorio, Roberto Vizza, Enrico Losito, Nunzia S. Greggi, Stefano |
| description | To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II–III serous borderline ovarian tumors (BOTs).
A multi-institutional retrospective study was conducted within the MITO Group.
A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91–179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5–57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6–167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT.
Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.
•Despite the high rate of recurrence, FSS provides good reproductive outcomes without a negative impact on overall survival.•The presence of invasive peritoneal implants affects the disease-free outcome with no impact on overall survival.•Advanced-stage serous BOTs can be safely selected for fertility-preservation management. |
| doi_str_mv | 10.1016/j.ygyno.2021.03.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2507148822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825821002614</els_id><sourcerecordid>2507148822</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-a0a178adf977139805914c6452cc64750ca9eae4e5cdbead50af19074bb5cac93</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EokvhFyAhH7kkjON4Ex84VFULlYp6KWdrYk8Wr_Kx2M5K6a_Hy5Yeucxc3mdezcPYRwGlALH9si_X3TrNZQWVKEGWUMlXbCNAq2LbKv2abQA0FG2l2gv2LsY9AEgQ1Vt2IWXTCqXqDXu6pZD84NNaxAMGP-14CoRppClxP3F0R5wsuSIm3BGPFOYl8m4OjsLgJ-LzMVM48bSMc4glv8rMhMMafeR9mEeefhH_cff4IGoe0-JW7jBhh5Heszc9DpE-PO9L9vP25vH6e3H_8O3u-uq-sFLpVCCgaFp0vW4aIXULSovabmtV2TwbBRY1IdWkrOsInQLshYam7jpl0Wp5yT6f7x7C_HuhmMzoo6VhwInyM6ZS0Ii6basqR-U5asMcY6DeHIIfMaxGgDlJN3vzV7o5STcgTZaeqU_PBUs3knth_lnOga_nAOU3j56CidbTSasPZJNxs_9vwR8hfJZi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507148822</pqid></control><display><type>article</type><title>Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Falcone, Francesca ; Breda, Enrico ; Ferrandina, Gabriella ; Malzoni, Mario ; Perrone, Anna M. ; Cormio, Gennaro ; Di Donato, Violante ; Frigerio, Luigi ; Mangili, Giorgia ; Raspagliesi, Francesco ; Festi, Anna ; Scibilia, Giuseppe ; Biglia, Nicoletta ; Sorio, Roberto ; Vizza, Enrico ; Losito, Nunzia S. ; Greggi, Stefano</creator><creatorcontrib>Falcone, Francesca ; Breda, Enrico ; Ferrandina, Gabriella ; Malzoni, Mario ; Perrone, Anna M. ; Cormio, Gennaro ; Di Donato, Violante ; Frigerio, Luigi ; Mangili, Giorgia ; Raspagliesi, Francesco ; Festi, Anna ; Scibilia, Giuseppe ; Biglia, Nicoletta ; Sorio, Roberto ; Vizza, Enrico ; Losito, Nunzia S. ; Greggi, Stefano</creatorcontrib><description>To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II–III serous borderline ovarian tumors (BOTs).
A multi-institutional retrospective study was conducted within the MITO Group.
A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91–179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5–57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6–167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT.
Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.
•Despite the high rate of recurrence, FSS provides good reproductive outcomes without a negative impact on overall survival.•The presence of invasive peritoneal implants affects the disease-free outcome with no impact on overall survival.•Advanced-stage serous BOTs can be safely selected for fertility-preservation management.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2021.03.023</identifier><identifier>PMID: 33781554</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Cytoreduction Surgical Procedures ; Databases, Factual ; Female ; Fertility Preservation ; Humans ; Italy ; Neoplasm Staging ; Neoplasms, Cystic, Mucinous, and Serous - mortality ; Neoplasms, Cystic, Mucinous, and Serous - pathology ; Neoplasms, Cystic, Mucinous, and Serous - surgery ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Pregnancy ; Pregnancy Outcome ; Prospective Studies ; Retrospective Studies ; Survival Analysis</subject><ispartof>Gynecologic oncology, 2021-06, Vol.161 (3), p.825-831</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-a0a178adf977139805914c6452cc64750ca9eae4e5cdbead50af19074bb5cac93</citedby><cites>FETCH-LOGICAL-c359t-a0a178adf977139805914c6452cc64750ca9eae4e5cdbead50af19074bb5cac93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825821002614$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33781554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falcone, Francesca</creatorcontrib><creatorcontrib>Breda, Enrico</creatorcontrib><creatorcontrib>Ferrandina, Gabriella</creatorcontrib><creatorcontrib>Malzoni, Mario</creatorcontrib><creatorcontrib>Perrone, Anna M.</creatorcontrib><creatorcontrib>Cormio, Gennaro</creatorcontrib><creatorcontrib>Di Donato, Violante</creatorcontrib><creatorcontrib>Frigerio, Luigi</creatorcontrib><creatorcontrib>Mangili, Giorgia</creatorcontrib><creatorcontrib>Raspagliesi, Francesco</creatorcontrib><creatorcontrib>Festi, Anna</creatorcontrib><creatorcontrib>Scibilia, Giuseppe</creatorcontrib><creatorcontrib>Biglia, Nicoletta</creatorcontrib><creatorcontrib>Sorio, Roberto</creatorcontrib><creatorcontrib>Vizza, Enrico</creatorcontrib><creatorcontrib>Losito, Nunzia S.</creatorcontrib><creatorcontrib>Greggi, Stefano</creatorcontrib><title>Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II–III serous borderline ovarian tumors (BOTs).
A multi-institutional retrospective study was conducted within the MITO Group.
A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91–179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5–57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6–167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT.
Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.
•Despite the high rate of recurrence, FSS provides good reproductive outcomes without a negative impact on overall survival.•The presence of invasive peritoneal implants affects the disease-free outcome with no impact on overall survival.•Advanced-stage serous BOTs can be safely selected for fertility-preservation management.</description><subject>Adult</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Databases, Factual</subject><subject>Female</subject><subject>Fertility Preservation</subject><subject>Humans</subject><subject>Italy</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - mortality</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - pathology</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - surgery</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EokvhFyAhH7kkjON4Ex84VFULlYp6KWdrYk8Wr_Kx2M5K6a_Hy5Yeucxc3mdezcPYRwGlALH9si_X3TrNZQWVKEGWUMlXbCNAq2LbKv2abQA0FG2l2gv2LsY9AEgQ1Vt2IWXTCqXqDXu6pZD84NNaxAMGP-14CoRppClxP3F0R5wsuSIm3BGPFOYl8m4OjsLgJ-LzMVM48bSMc4glv8rMhMMafeR9mEeefhH_cff4IGoe0-JW7jBhh5Heszc9DpE-PO9L9vP25vH6e3H_8O3u-uq-sFLpVCCgaFp0vW4aIXULSovabmtV2TwbBRY1IdWkrOsInQLshYam7jpl0Wp5yT6f7x7C_HuhmMzoo6VhwInyM6ZS0Ii6basqR-U5asMcY6DeHIIfMaxGgDlJN3vzV7o5STcgTZaeqU_PBUs3knth_lnOga_nAOU3j56CidbTSasPZJNxs_9vwR8hfJZi</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Falcone, Francesca</creator><creator>Breda, Enrico</creator><creator>Ferrandina, Gabriella</creator><creator>Malzoni, Mario</creator><creator>Perrone, Anna M.</creator><creator>Cormio, Gennaro</creator><creator>Di Donato, Violante</creator><creator>Frigerio, Luigi</creator><creator>Mangili, Giorgia</creator><creator>Raspagliesi, Francesco</creator><creator>Festi, Anna</creator><creator>Scibilia, Giuseppe</creator><creator>Biglia, Nicoletta</creator><creator>Sorio, Roberto</creator><creator>Vizza, Enrico</creator><creator>Losito, Nunzia S.</creator><creator>Greggi, Stefano</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202106</creationdate><title>Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database</title><author>Falcone, Francesca ; Breda, Enrico ; Ferrandina, Gabriella ; Malzoni, Mario ; Perrone, Anna M. ; Cormio, Gennaro ; Di Donato, Violante ; Frigerio, Luigi ; Mangili, Giorgia ; Raspagliesi, Francesco ; Festi, Anna ; Scibilia, Giuseppe ; Biglia, Nicoletta ; Sorio, Roberto ; Vizza, Enrico ; Losito, Nunzia S. ; Greggi, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-a0a178adf977139805914c6452cc64750ca9eae4e5cdbead50af19074bb5cac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Databases, Factual</topic><topic>Female</topic><topic>Fertility Preservation</topic><topic>Humans</topic><topic>Italy</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - mortality</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - pathology</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - surgery</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Falcone, Francesca</creatorcontrib><creatorcontrib>Breda, Enrico</creatorcontrib><creatorcontrib>Ferrandina, Gabriella</creatorcontrib><creatorcontrib>Malzoni, Mario</creatorcontrib><creatorcontrib>Perrone, Anna M.</creatorcontrib><creatorcontrib>Cormio, Gennaro</creatorcontrib><creatorcontrib>Di Donato, Violante</creatorcontrib><creatorcontrib>Frigerio, Luigi</creatorcontrib><creatorcontrib>Mangili, Giorgia</creatorcontrib><creatorcontrib>Raspagliesi, Francesco</creatorcontrib><creatorcontrib>Festi, Anna</creatorcontrib><creatorcontrib>Scibilia, Giuseppe</creatorcontrib><creatorcontrib>Biglia, Nicoletta</creatorcontrib><creatorcontrib>Sorio, Roberto</creatorcontrib><creatorcontrib>Vizza, Enrico</creatorcontrib><creatorcontrib>Losito, Nunzia S.</creatorcontrib><creatorcontrib>Greggi, Stefano</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falcone, Francesca</au><au>Breda, Enrico</au><au>Ferrandina, Gabriella</au><au>Malzoni, Mario</au><au>Perrone, Anna M.</au><au>Cormio, Gennaro</au><au>Di Donato, Violante</au><au>Frigerio, Luigi</au><au>Mangili, Giorgia</au><au>Raspagliesi, Francesco</au><au>Festi, Anna</au><au>Scibilia, Giuseppe</au><au>Biglia, Nicoletta</au><au>Sorio, Roberto</au><au>Vizza, Enrico</au><au>Losito, Nunzia S.</au><au>Greggi, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2021-06</date><risdate>2021</risdate><volume>161</volume><issue>3</issue><spage>825</spage><epage>831</epage><pages>825-831</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II–III serous borderline ovarian tumors (BOTs).
A multi-institutional retrospective study was conducted within the MITO Group.
A total of 91 patients were recruited. The median follow-up time from primary cytoreduction was 127 months (IQR range 91–179). Forty-nine patients (53.8%) experienced at least one recurrence (median time to first relapse 22 months, IQR range 9.5–57). At univariable analysis, significant predictors of relapse were: size of largest extra-ovarian lesion, peritoneal cancer index, completeness of cytoreduction, type of implants. After multivariable analysis, the size of extra-ovarian lesions and the presence of invasive implants resulted as the only independent predictors of recurrence. Median disease-free survival (DFS) was 96 months (95% CI, 24.6–167.3), while median disease-specific survival (DSS) was not reached. Twenty-nine patients (31.8%) attempted to conceive: 20 (68.9%) achieved at least one pregnancy and 18 (62%) gave birth to a healthy child. At the end of the observation period, 88 patients (96.7%) showed no evidence of disease, 2 (2.2%) were alive with disease, and 1 patient (1.1%) died from BOT.
Despite the recurrence high rate, FSS provides good chances of reproductive success with no impact on DSS. The presence of invasive peritoneal implants affects the DFS but not DSS nor reproductive outcome. The risk of recurrence would not seem to be related to the ovarian preservation per se, but to the natural history of the initial peritoneal spread.
•Despite the high rate of recurrence, FSS provides good reproductive outcomes without a negative impact on overall survival.•The presence of invasive peritoneal implants affects the disease-free outcome with no impact on overall survival.•Advanced-stage serous BOTs can be safely selected for fertility-preservation management.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33781554</pmid><doi>10.1016/j.ygyno.2021.03.023</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2021-06, Vol.161 (3), p.825-831 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2507148822 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Cytoreduction Surgical Procedures Databases, Factual Female Fertility Preservation Humans Italy Neoplasm Staging Neoplasms, Cystic, Mucinous, and Serous - mortality Neoplasms, Cystic, Mucinous, and Serous - pathology Neoplasms, Cystic, Mucinous, and Serous - surgery Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Pregnancy Pregnancy Outcome Prospective Studies Retrospective Studies Survival Analysis |
| title | Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A35%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fertility-sparing%20treatment%20in%20advanced-stage%20serous%20borderline%20ovarian%20tumors.%20An%20analysis%20from%20the%20MITO14%20study%20database&rft.jtitle=Gynecologic%20oncology&rft.au=Falcone,%20Francesca&rft.date=2021-06&rft.volume=161&rft.issue=3&rft.spage=825&rft.epage=831&rft.pages=825-831&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2021.03.023&rft_dat=%3Cproquest_cross%3E2507148822%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2507148822&rft_id=info:pmid/33781554&rft_els_id=S0090825821002614&rfr_iscdi=true |